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Residual HIV-RNA Levels Persist for Up to 2.5 Years in
Peripheral Blood Mononuclear Cells of Patients on 
Potent Antiretroviral Therapy
MAREK FISCHER,1 HULDRYCH F. GÜNTHARD,1 MILOS OPRAVIL,1 BEDA JOOS,1
WERNER HUBER,1,5 LESLIE R. BISSET,2 PETER OTT,3 JÜRG BÖNI,4
RAINER WEBER,1 and RICHARD W. CONE1
ABSTRACT
The long-term response of 10 asymptomatic, antiretroviral therapy-naive HIV-1-infected patients to potent
combination  antiretroviral therapy was characterized by monitoring levels of HIV-1 RNA in plasma, pe-
ripheral blood mononuclear cells (PBMC), and lymphoid tissue using highly sensitive HIV-1 RNA assays.
Although plasma viral loads were continuously suppressed to levels below 50 HIV-1 RNA copies/ml for up
to 2.5 years (60–128 weeks), HIV-1 RNA was still detectable at very low levels (1 to 49 HIV-1 RNA copies/ml)
in 25% of the samples. In corresponding PBMC specimens, residual HIV-RNA was detectable in as much
as 91% of samples tested (1 to 420 HIV-1 RNA copies/mg total RNA). Similarly, HIV-1 RNA levels in lym-
phoid tissue also remained detectable at a high frequency (86%). A highly significant correlation was demon-
strated between therapy-induced change in PBMC HIV-1 RNA levels and change in plasma HIV-1 RNA
levels (r2 5 0.69; p 5 0.003). These findings support the concept that measurement of HIV-1 RNA in the
easily accessible PBMC compartment is relevant for evaluating the potency of current and future anti-
retroviral therapies.
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COM BINATIO N ANTIRE TR OVIRA L DRUG TH E RA PY can suppressHIV-1 replication, 1 resulting in marked clinical benefit.2–4
Plasma HIV-1 RNA quantitation is most widely used to assess
an individual’ s virological status both for prediction of the sub-
sequent clinical course 5 and for monitoring the treatment re-
sponse. 6 Similar to plasma viral load, levels of cell-associated
HIV-1 RNA are predictive of clinical progression. 7,8 In addi-
tion, levels of HIV-1 RNA in lymphoid tissue, the presumed
major reservoir of HIV-1,9 may provide information about
residual viral activity in this reservoir for patients with unde-
tectable plasm a RNA levels.10,11 However, the limited accessi-
bility of lymphoid tissue precludes the use of routine sampling
for monitoring HIV therapy.
In this report we have determined HIV-1 RNA levels in
plasma, PBMC, and lymphoid tissue in patients on potent long-
term antiretroviral therapy to assess the sensitivity of these vi-
rological measurements for detection of residual HIV-RNA.
HIV-1-infected , asymptomatic,  treatment-naive patients with
. 400 CD4 cells/ m l at enrollment were randomly assigned to
receive triple therapy [AZT 300 mg bid, 3TC 150 mg bid, and
ritonavir (RTV) 600 mg bid] in a prospective, open-label trial
called the Swiss EARTH study.12 A subset of 10 individuals
treated initially with triple drug regimens [50% female, aver-
age age 32 6 5 years (mean 6 SD)] with follow-up data avail-
able at least up to Week 96 and plasma viral load suppressed
permanently to levels below 50 copies/ ml during the second
and the third year of therapy was selected for the present study.
Due to side effects, two patients (patients 9 and 10) discontin-
ued RTV and in two patients RTV was replaced by nelfinavir
(NFV) 750 mg tid (Table 1). From a subset of five patients bi-
Divisions of 1Infectious Diseases and 2Clinical Immunology, Department of Internal Medicine, and the 3Clinic for Ear, Nose and Throat
Surgery, University Hospital Zurich, 4Swiss National Centre for Retroviruses, University of Zurich, Zurich, Switzerland.
5Current address: F. Hoffmann-La Roche, Basel, Switzerland.
lateral tonsil biopsies were obtained at Weeks 0, 4, 24, and 48
and from 1 subject at Weeks 0, 4, 24, 48, and 96. In one pa-
tient fine-needle biopsies from lymph nodes were available at
Weeks 0 and 24.
After initiation of treatment, plasm a HIV-RNA in all study
patients reached levels below 50 copies/ml in a median (min;
max) time of 12 (4; 36) weeks and subsequently remained be-
low 50 copies for a median duration of 105 (60; 128) weeks.
Overall, in 25% of plasma specimens obtained during the sec-
ond and third year of therapy HIV-1 RNA (time points after
Week 47) was measured at very low but detectable levels. For
individual patients detectable plasma viral loads were observed
with a frequency of 9% to 50% at time points after Week 47.
From one patient (patient 6), all specimens and from two pa-
tients (patients 4 and 5) none were found to have detectable
plasm a HIV-1 RNA.
In contrast to plasma, HIV-1 RNA remained detectable in
the vast majority (91%) of PBMC specimens. In seven patients
(patients 1, 2, 4, 5, 7, 8, and 9) PBMC-associated HIV-1 RNA
was detectable in 100% of the specim ens. Lower frequencies
(92, 89, and 42%, respectively) were observed in three patients
(patients 3, 6, and 10, respectively). The mean PBMC-associ-
ated HIV-1 RNA levels measured after 1 year of therapy
( . Week 47), henceforth referred to as nadir HIV-1 RNA lev-
els, plateaued during the second and third year of therapy (Fig.
1B) as confirmed by the finding that no patient showed a sig-
nificant trend for a decrease of PBMC-associated HIV-1 RNA
during the second or third year of therapy (Spearm an nonpara-
metrical analysis, p .  0.18).
Similarly as in PBMC, very few specim ens from lymphoid
tissue had undetectable HIV-1 RNA: Only 3 of 27 samples were
HIV-1 RNA negative: two from patient 5 and one from patient
8. The very low yield of total RNA extracted from each of these
specimens may explain the negative results.
After initiation of therapy, changes in HIV-1 RNA levels in
PBMC and lymphoid tissue paralleled changes in plasma HIV-
1 RNA (Fig. 1). HIV-1 RNA levels in plasm a and PBMC were
significantly correlated at baseline (r2 5 0.41; p 5 0.05; n 5
10) and throughout the observation period (r2 5 0.46; p ,
0.0001; n 5 62) (Fig. 2). Significant correlation of HIV-RNA
levels in lymphoid tissue compared to either PBMC or plasma
HIV-1 RNA levels was demonstrated for the whole observa-
tion period (r2 5 0.40; p 5 0.001; n 5 23 and r2 5 0.54; p 5
0.002; n 5 15, respectively) but not for the data at baseline (p .
0.25; n 5 6).
Virological response 13 to therapy was calculated as the ratio
of the nadir HIV-1 RNA levels divided by the baseline level
for each individual patient in plasma, PBMC, and lymphoid tis-
sue. Virological responses in PBMC and plasma were highly
correlated (r2 5 0.69; p 5 0.003; n 5 10) (Fig. 3). This corre-
lation remained significant, when the analysis was recalculated
assuming that PCR-negative specimens contained zero copies
(r2 5 0.54; p 5 0.04; n 5 8). However, the comparison of vi-
rological response in lymphoid tissue to PBMC failed to show
significant correlation (p . 0.4; n 5 6).
Two main observations were made in this study:
1. In patients treated with potent antiretroviral therapy, PBMC-
associated HIV-1 RNA persisted for up to 2 years or longer
at levels as low as 5–10 copies/ m g total RNA and did not
show a tendency to decay further during the second year of
therapy.
2. Virological response to therapy in plasma was mirrored by
the response in PBMC-associated HIV-1 RNA with the mea-
surem ent in the cellular compartment being much more sen-
sitive.
Unlike plasm a viremia, levels of HIV-1 RNA in PBMC and
lymphoid tissue rarely became undetectable. PBMC-associated
HIV-1 RNA was found to persist for up to 2.5 years of ther-
apy. Furtado and colleagues 14 recently reported persistence of
PBMC-associated HIV-RNA in five patients under potent an-
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TABLE 1. PATIE NT CH ARACTER ISTIC S
Patient Therapy
Plasmab PBMC d Lymphoid tissued
Follow-up
ID start Change (weeka) Baseline Nadir c Baseline Nadir c Baseline Nadir e weeks
1 AZT/3TC/RTV AZT/3TC/NFV (7) 5028 # 5 99 5 nd nd 96
2 AZT/3TC/RTV 1406 # 12 214 16 54056 6 114
3 AZT/3TC/RTV 9995 # 9 252 # 5 115812 343 124
4 AZT/3TC/RTV AZT/3TC/NFV (12) 3725 , 6 288 13 ndf nd 96
5 AZT/3TC/RTV 32595 , 7 431 6 557124 , 12 132
6 AZT/3TC/RTV 30202 17 978 24 21025 6 108
7 AZT/3TC/RTV 36835 # 10 2789 49 36450 11 126
8 AZT/3TC/RTV 9154 # 9 3155 111 192514 nd 126
9 AZT/3TC/RTV AZT/3TC (80) 35574 # 14 2138 49 nd nd 102
10 AZT/3TC/RTV AZT/3TC (13) 8555 # 8 244 # 4 14109 477 132
aStudy week in which therapy was changed.
bHIV-1 RNA copies/ml.
cMean HIV RNA levels after study Week 47 ( , signifies that undetectable values were obtained throughout the observation
period and # means that some HIV-RNA levels were detectable and some were not).
dHIV-1 RNA copies/ m g total RNA.
eHIV-RNA levels at study Week 48 ( , signifies the detection limit of an undetectable value).
fnd, no data available.
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FIG. 1. HIV-1 RNA levels in plasm a, PBMC, and lymphoid
tissue during long-term antiretroviral therapy. Solid lines con-
nect datapoints from individual patients. Filled circles indicate
undetectable measurements and their individual limits of de-
tection. Dotted lines parallel to x-axes show median, maximal,
and minimal detection limits for RNA measurem ents in each
compartment. (A) Plasma HIV-1 RNA was determined by the
Amplicor HIV-1 Monitor Test and ultrasensitive modifica-
tions.34,3 5 (B) PBMC HIV-1 RNA. (C) HIV-1 RNA in lym-
phoid tissue. Lymphoid tissue biopsies were processed as de-
scribed previously. 17 Measurements of HIV-1 RNA in PBMC
and lymphoid tissue were performed by a modification of the
Amplicor Test.12,35
FIG. 2. Correlation between HIV-1 RNA levels in PBMC, plasma, and lymphoid tissue. Combined data from all patients dur-
ing the whole observation period are shown. Detectable log10 transformed HIV-1 HIV RNA measurements were used for this
analysis. N, number of datapoints; R2, Pearson correlation coefficient; P, level of significance. Solid and dotted lines show cal-
culated linear regression curves and their 95% confidence intervals, respectively, with the following underlying equations: (A)
HIV-RNA in PBMC compared to plasma; y 5 1.05x 1 0.34. (B) HIV-RNA in PBMC compared to lymphoid tissue; y 5 1.15x 1
0.93. (C) HIV-RNA in plasma compared to lymphoid tissue; y 5 0.97x 1 0.56.
tiretroviral therapy. Our findings extend this observation show-
ing that at least for the chronically infected asymptomatic pa-
tients studied here, such persistence can be stable in that no fur-
ther decrease of PBMC-associated HIV-1 RNA was observed
in the second year of treatment.
The question has been posed whether the residual cellular
HIV-RNA persisting in PBMC reflects intracellula r transcripts
of infected cells or residual virions attached to the outside of
uninfected cells15—in analogy to extracellula r viral particles
trapped in lymphoid tissue. 16 –18 Consistent with the hypoth-
esis that residual PBMC-associat ed HIV-1 RNA may be, in
part or entirely, extracellul ar, it was observed that 25% of
plasm a specim ens tested after Week 47 showed detectable
HIV-1 RNA at low levels (all below  50 copies/ ml). This ob-
servation, in agreement with a recent report, 19 shows that cur-
rent antiretrovi ral therapies may not completely  suppress
virion production.
However, we did not observe elevated nadir levels of PBMC-
associated HIV-1 RNA in the patients with actually detectable
plasma viremia after 1 year of therapy (data not shown), which
might be expected under the assum ption that PBMC-associated
HIV-1 RNA would merely reflect residual virions bound to the
surface of uninfected cells.
If residual PBMC-associated HIV-1 RNA were located in-
tracellularly, the question would arise whether such cellular
transcripts originate from chronically or productively infected
cells. Observations of other investigators indicate that both may
apply. In particular, there is evidence that active viral replica-
tion may persist in the presence of treatment with potent anti-
retroviral therapy.20–22 Conversely, the persistence of PBMC-
associated HIV-1 RNA may be based on latency of long-lived
infected cells23–25 transcribing HIV-RNA at very low levels.
Reminiscent of our observations, uninduced J1.1 cells—chron-
ically infected T-lymphocytes —have been reported to express
low levels of predominantly unspliced HIV-1 RNA in at least
a fraction of cells.26
Comparison of HIV-1 RNA levels from the different com-
partments revealed that virological  response in plasma mir-
rored response in PBMC with remarkable accuracy. The ra-
tional for having defined virological  response in our patients
by the ratio of baseline and nadir HIV-1 RNA levels13 was
based on observation s that found “high baseline” 27– 29 and
“high nadir levels” 30,31 of plasma virem ia to be predictors for
virological  failure of antiretrovir al therapy. Reminiscent  of the
correlation  of virological responses, PBMC HIV-1 RNA lev-
els were also directly correlated with viral RNA levels in
plasma at baseline and throughout  the whole observation  pe-
riod. The finding that correlation  was weaker (r2 5 0.46) in
the direct comparison  than in the paired analysis of virologi-
cal responses (r2 5 0.69) may be due to the high patient-to-
patient variation observed in PBMC-associated HIV-1 RNA
levels (coefficient s of variations at baseline and nadir of 111
and 120%, respectively ). Correlation of PBMC-associated
HIV-1 RNA levels with viral RNA load in lymphoid tissue
was also demonstrated. However, baseline HIV-1 RNA lev-
els as well as the virological response in lymphoid tissue failed
to show significant  correlation  with either plasma or PBMC.
Such discordance  can be expected because the vast majority
of HIV-1 RNA in lymphoid tissue of untreated patients rep-
resent extracellula r virions bound to follicular dendritic
cells,16 which may be saturated at baseline. 16,32 It has also
been claimed that HIV-1 RNA associated with mononuclear
cells in lymph nodes reflects plasm a viremia better than fol-
licular dendritic cell-associa ted HIV-1 RNA.32 Confirm ing the
latter assum ption, strong correlation  between viral load in pu-
rified lymph node mononucle ar cells and PBMC viral load has
been reported. 33
In conclusion, the data presented here suggest that measure-
ments of PBMC-associated HIV-1 RNA may permit assessment
of virological response even among patients with permanently
undetectable plasma viral loads, when the distinction between
“potent”  and “very potent”  antiretroviral therapy may otherwise
be impossible.
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FIG. 3. Correlation between virologic response of HIV-1
RNA levels in PBMC and plasma to antiretroviral therapy. Vi-
rological responses 13 of HIV-1 RNA levels were plotted as
log10 (nadir HIV-1 RNA levels/baseline HIV-1 RNA levels).
N, number of data points; R2, Pearson correlation coefficient;
P, level of significance. The solid line shows the calculated lin-
ear regression curve and its 95% confidence intervals (dotted
lines) with the follow ing underlying equation: y 5 0.46x 2
0.13.
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